As the development of checkpoint inhibitor therapy, five immunotherapy agents targeting the primarily targeting programmed cell death-1 protein (PD-1) or its ligand (PD-L1) pathway have been approved by the US Food and Drug Administration (FDA) for BC patients, including atezolizumab, pembrolizumab, avelumab, nivolumab, and durvalumab. The gene discussed is CD274; the disease is breast cancer.